Envoy Medical Corporation manufactures and markets an implantable hearing aid device. The company is headquartered in White Bear Lake, Minnesota.
| Revenue (TTM) | 207,000 |
| Gross Profit (TTM) | -608,000 |
| EBITDA | $-23.13M |
| Operating Margin | -10920.00% |
| Return on Equity | 0.00% |
| Return on Assets | -86.50% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $-4.07 |
| Price-to-Book | 14.90 |
| Price-to-Sales (TTM) | 267.33 |
| EV/Revenue | 178.17 |
| EV/EBITDA | -1.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -34.60% |
| Shares Outstanding | $7.74M |
| Float | $4.32M |
| % Insiders | 40.23% |
| % Institutions | 23.29% |
Volatility is currently expanding
Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $3.5 per share a year ago.
Management Will Host a Conference Call at 4:30 P.M. ET on the Same Day White Bear Lake, Minnesota--(Newsfile Corp. - October 27, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced it will report its financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026.
White Bear Lake, Minnesota--(Newsfile Corp. - October 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it will implement a 1-for-10 reverse stock split of its outstanding shares of Class A common stock ("Common Stock"), effective at 12:01 a.m. Eastern Time on October 26, 2026 (the "Reverse Split").
Company Believes It Is the First to Reach This Milestone in a U.S. Pivotal Trial of a Fully Implanted Cochlear Implant Remains on Track to Reach 12-Month Visit Milestone by Early Q2 2027 and Submit Final Clinical PMA Module by End of Q2 2027 White Bear Lake, Minnesota--(Newsfile Corp. - October 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it has surpassed the six-month follow-up visit milestone for the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This milestone signifies the halfway point in the trial's final stage of data collection as each participant is followed for a total of 12 months.
Second of Four Planned Modules Moves Rolling FDA Review Forward Advances Toward Targeted Completion of the Final Clinical Module Submission in Q2 2027 White Bear Lake, Minnesota--(Newsfile Corp. - October 12, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced the submission of the second module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for the Acclaim® cochlear implant, which has received FDA Breakthrough Device Designation. The second module, which included primarily engineering information, follows the Company's submission of the first module on June 30, 2026.
Canadian and Hong Kong Patents Continue to Strengthen Intellectual Property Protection Across Envoy Medical's Fully Implanted Hearing Platform White Bear Lake, Minnesota--(Newsfile Corp. - September 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the grant of two additional international patents, expanding its global intellectual property portfolio to 97 patents, consisting of 40 U.S. and 57 foreign patents. In addition, the Company has 26 pending foreign applications and 9 pending U.S. applications.
White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medical ® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, on September 14-16, 2026 at the Lotte New York Palace Hotel in New York City.
Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.32 per share a year ago.
Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement in Speech Perception White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported financial results for the second quarter ended June 30, 2026, and provided a business update, highlighting continued execution on its corporate initiatives. "The second quarter moved us measurably closer to bringing our fully implanted cochlear implant to market," said Brent Lucas, Chief Executive Officer of Envoy Medical.
Envoy Medical, Inc. (COCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on COCH and any ticker you trade — then tracks every position and per-strategy win rate.
